#c difficile

[dxmedicalstudent]

There are some smells... unique to working in healthcare. Smells that you don’t (or really shouldn’t) smell elsewhere. Once you learn what they smell like, you never truly forget. Deal with one of them, and even when you’re home and showered, you might get the feeling you can smell it still. Even thinking about them is enough to conjure a vivid sensory memory.

[nuadox]

A new study has shown that an mRNA vaccine protected mice against deadly intestinal C. difficile

- By Nuadox Crew -

Researchers have developed an mRNA vaccine targeting Clostridioides difficile (C. difficile), a severe intestinal pathogen responsible for about 30,000 deaths annually in the U.S.

This new vaccine showed promising results in mice, offering protection from severe illness and death after exposure to lethal doses of the bacteria.

Unlike conventional vaccines, the mRNA version triggered a broad immune response, including antibodies and T cells. Vaccinated mice survived, experiencing only mild symptoms, and maintained immunity for six months.

While the vaccine has yet to be tested on humans, early studies in rhesus macaques suggest it might also elicit an immune response in primates.

However, more research, including testing on "dirty mice" with more naturalistic immune systems, is needed before moving to human trials.

Header image: Clostridioides difficile pathogen. Credit: National Foundation for Infectious Diseases (NFID).

Read more at Science News

Scientific paper: Alameh, M., Semon, A., Bayard, N. U., Pan, Y., Dwivedi, G., Knox, J., Glover, R. C., Rangel, P. C., Tanes, C., Bittinger, K., She, Q., Hu, H., Bonam, S. R., Maslanka, J. R., Planet, P. J., Moustafa, A. M., Davis, B., Chevrier, A., Beattie, M., . . . Zackular, J. P. (2024). A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science, 386(6717), 69–75. https://doi.org/10.1126/science.adn4955

Other recent news

Israel at COP29: Israel will showcase 20 climate-tech firms at the COP29 Climate Conference in Baku,Azerbaijan. These companies offer solutions in fields such as emissions, pollution, and carbon capture.

Revolutionary Super Polymer: Researchers at Osaka University have developed a new type of polymer that is unbelievably tough and endlessly recyclable.

Hubble's Galactic Masterpiece: The Hubble Space Telescope has unveiled a stunning image of NGC 5248, a spiral galaxy located 42 million light-years away.

Brain-Controlled Bionic Limbs: Advances in brain-controlled bionic limbs are inching closer to reality, offering new possibilities for individuals with mobility impairments.

[muslim-flint]

flemme de liker et répondre so true bestie à chaque post mais tu me régales

content que ça te plaise parce que je traverse chaque cercle de l'enfer un par un

[cdifffoundation]

JAMA: Prevalence of Detection of CDI (C. difficile) Among Asymptomatic Children, A Systematic Review and Meta-analysis

JAMA: Prevalence of Detection of CDI (C. difficile) Among Asymptomatic Children, A Systematic Review and Meta-analysis

      Sarah R. Tougas, BScN, MD1; Nidhi Lodha, MBBS, MSc1; Ben Vandermeer, PhD2; et alDiane L. Lorenzetti, PhD3; Phillip I. Tarr, MD4,5; Gillian A. M. Tarr, PhD6; Linda Chui, PhD7; Otto G. Vanderkooi, MD8,9; Stephen B. Freedman, MDCM, MSc10,11 JAMA Pediatr. Published online August 2, 2021. doi:10.1001/jamapediatrics.2021.2328   Question  What is the prevalence of Clostridioides…

View On WordPress

[cdifffoundation]

Contagion Live Presents: Where Are We With Clostridioides Difficile?

Contagion Live Presents: Where Are We With Clostridioides Difficile?

MEDIA PARTNER In this episode, our 1 Big Question is: Looking at C diff as a whole, would you say the medical community is doing a better job overall of treatment and what challenges remain? We interviewed Sahil Khanna, MBBS, MS, who is professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic; Glenn Tillotson, PhD, FIDSA, FCCP, GST Micro LLC; Payal K. Patel, MD,…

View On WordPress

[cdifffoundation]

American Society of Colon and Rectal Surgeons (ASCRS) June 2021 Clinical Practice Guidelines: Management of a CDI

American Society of Colon and Rectal Surgeons (ASCRS) June 2021 Clinical Practice Guidelines: Management of a CDI

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection Poylin, Vitaliy M.D.1; Hawkins, Alexander T. M.D., M.P.H.2; Bhama, Anuradha R. M.D.3; Boutros, Marylise M.D.4; Lightner, Amy L. M.D.5; Khanna, Sahil M.B.B.S., M.S.6; Paquette, Ian M. M.D.7; Feingold, Daniel L. M.D.8; Prepared by the Clinical Practice Guidelines…

View On WordPress

[cdifffoundation]

          Increased risk for Clostridium difficile (C diff) infection remained elevated for up to a year after the conclusion of treatment with proton-pump inhibitors (PPIs), according to a paper published in Clinical Infectious Diseases.   Malin Inghammar, PhD Source and to read the article in its entirety please click on the following link to be…

View On WordPress

[cdifffoundation]

MGB Biopharma Developing MGB-BP-3 a Treatment for CDI - Announces the Successful Completion of Its End-of-Phase 2 Meeting With the FDA

MGB Biopharma Developing MGB-BP-3 a Treatment for CDI – Announces the Successful Completion of Its End-of-Phase 2 Meeting With the FDA

MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI), today announces the successful completion of its End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (FDA), an important milestone for the company and its lead product. The EOP2 Meeting is a formal step at which companies seek confirmation…

View On WordPress